ROTH Capital Initiates Equity Research Analyst Coverage on Biovest

TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB: BVTI) today announced that ROTH Capital Partners, LLC initiated equity research coverage on the Company with a "Buy" recommendation and a 12-month price target of $2.00 per share. The new report, issued this week, was authored by Joseph Pantginis, Ph.D., Senior Research Analyst at ROTH.

To request a copy of the report, please contact ROTH Capital's sales desk at 1-800-933-6830.

Neither Biovest International, Inc., nor any of its affiliates, endorse, confirm or adopt the contents of the ROTH Capital Equity Research Report nor accept any responsibility for its accuracy which is the sole responsibility of its author. Biovest undertakes no obligation to revise or update this Report to reflect events or circumstances after its issuance or otherwise. The reader should review all disclaimers contained in this Report. Biovest is subject to significant risks, and a discussion of such risks can be found by reviewing Biovest's SEC filings including Annual and Quarterly Reports as filed on Form 10-K and Form 10-Q respectively.

About Biovest International, Inc.

Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin's lymphoma.

Headquartered in Tampa, Florida with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the OTCQBTM Market with the stock-ticker symbol "BVTI", and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: "ABPI").

For further information, please visit: http://www.biovest.com

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.